Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 253

1.

Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.

Nutahara K, Higashihara E, Horie S, Kamura K, Tsuchiya K, Mochizuki T, Hosoya T, Nakayama T, Yamamoto N, Higaki Y, Shimizu T.

Nephron Clin Pract. 2005;99(1):c18-23.

PMID:
15637459
2.

Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease.

Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW.

Am J Kidney Dis. 2000 Mar;35(3):427-32.

PMID:
10692268
3.

Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.

Okura T, Kojima M, Machida H, Sugiyama M, Kato T, Komada T, Miyazaki T, Ninomiya T, Ichikawa T, Nakatani K, Watanabe Y, Dohi Y, Ito M, Kimura G.

J Hum Hypertens. 2012 Apr;26(4):214-9. doi: 10.1038/jhh.2011.22. Epub 2011 Mar 17.

PMID:
21412266
4.

Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).

Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, Ohe T, Ohtsu H, Kato T, Kamakura S, Kumagai K, Kurachi Y, Koretsune Y, Saikawa T, Sakurai M, Sato T, Sugi K, Nakaya H, Hirai M, Hirayama A, Fukatani M, Mitamura H, Yamazaki T, Watanabe E, Ogawa S; J-RHYTHM II Investigators.

Europace. 2011 Apr;13(4):473-9. doi: 10.1093/europace/euq439. Epub 2010 Dec 10.

PMID:
21148662
5.

ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.

Ogihara T, Fujimoto A, Nakao K, Saruta T; CASE-J Trial Group.

Expert Rev Cardiovasc Ther. 2008 Oct;6(9):1195-201. doi: 10.1586/14779072.6.9.1195.

PMID:
18939907
6.

Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.

Homma K, Hayashi K, Kanda T, Yoshioka K, Takamatsu I, Tatematsu S, Kumagai H, Wakino S, Saruta T.

J Hum Hypertens. 2004 Dec;18(12):879-84.

PMID:
15295613
7.

Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex).

Ueshima K, Oba K, Yasuno S, Fujimoto A, Sato T, Fukiyama K, Azuma J, Ogihara T, Saruta T, Nakao K; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group.

Contemp Clin Trials. 2009 Jan;30(1):97-101. doi: 10.1016/j.cct.2008.09.006. Epub 2008 Sep 13.

PMID:
18824134
8.

Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).

Maeda A, Tamura K, Kanaoka T, Ohsawa M, Haku S, Azushima K, Dejima T, Wakui H, Yanagi M, Okano Y, Fujikawa T, Toya Y, Mizushima S, Tochikubo O, Umemura S.

Clin Exp Hypertens. 2012;34(4):249-57. doi: 10.3109/10641963.2012.681081. Epub 2012 May 9.

PMID:
22571446
9.

Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.

Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T; Japanese Lasartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators.

Clin Exp Nephrol. 2003 Sep;7(3):221-30.

PMID:
14586719
11.

Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.

Kuriyama S, Tomonari H, Tokudome G, Horiguchi M, Hayashi H, Kobayashi H, Ishikawa M, Hosoya T.

Hypertens Res. 2002 Nov;25(6):849-55.

12.

Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats.

Sueta D, Nakamura T, Dong YF, Kataoka K, Koibuchi N, Yamamoto E, Toyama K, Yasuda O, Ogawa H, Kim-Mitsuyama S.

Am J Hypertens. 2012 Jun;25(6):704-10. doi: 10.1038/ajh.2012.26. Epub 2012 Mar 15.

PMID:
22421905
13.

Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.

London G, Schmieder R, Calvo C, Asmar R.

Am J Hypertens. 2006 Jan;19(1):113-21.

PMID:
16461202
14.

Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.

Saruta T, Hayashi K, Ogihara T, Nakao K, Fukui T, Fukiyama K; CASE-J Study Group.

Hypertens Res. 2009 Jun;32(6):505-12. doi: 10.1038/hr.2009.44. Epub 2009 Apr 24. Erratum in: Hypertens Res. 2009 Dec;32(12):1157.

PMID:
19390535
15.

Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).

Ogihara T, Ueshima K, Nakao K, Fukiyama K, Oba K, Yasuno S, Fujimoto A, Sato T, Matsuoka H, Saruta T; CASE-J Ex Study Group.

Hypertens Res. 2011 Dec;34(12):1295-301. doi: 10.1038/hr.2011.120. Epub 2011 Aug 11.

PMID:
21833000
16.

Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients.

Ishimitsu T, Kobayashi T, Honda T, Takahashi M, Minami J, Ohta S, Inada H, Yoshii M, Ono H, Matsuoka H.

Hypertens Res. 2005 Apr;28(4):351-9.

PMID:
16138566
17.

Renoprotective effects of benidipine in combination with angiotensin II type 1 receptor blocker in hypertensive Dahl rats.

Yao K, Sato H, Ina Y, Suzuki K, Ohno T, Shirakura S.

Hypertens Res. 2003 Aug;26(8):635-41.

18.

Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.

Abe M, Maruyama N, Suzuki H, Fujii Y, Ito M, Yoshida Y, Okada K, Soma M.

Hypertens Res. 2012 Aug;35(8):874-81. doi: 10.1038/hr.2012.45. Epub 2012 May 17.

PMID:
22592665
19.

Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.

Katayama S, Yagi S, Yamamoto H, Yamaguchi M, Izumida T, Noguchi Y, Inaba M, Inukai K.

Hypertens Res. 2007 Jun;30(6):529-33.

PMID:
17664856
20.

Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.

Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group.

Hypertension. 2008 Feb;51(2):393-8. doi: 10.1161/HYPERTENSIONAHA.107.098475. Epub 2008 Jan 2.

Supplemental Content

Support Center